Celcuity (NASDAQ:CELC) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Celcuity (NASDAQ:CELC) in a research report sent to investors on Thursday morning, MarketBeat.com reports. The firm issued an overweight rating and a $157.00 target price on the stock.

Several other research firms have also issued reports on CELC. HC Wainwright reaffirmed a “buy” rating and issued a $155.00 target price on shares of Celcuity in a report on Friday, August 14th. Wells Fargo & Company reduced their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Guggenheim raised their target price on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Craig Hallum reaffirmed a “buy” rating and set a $178.00 target price on shares of Celcuity in a research report on Wednesday, July 15th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $154.75.

Celcuity Stock Down 5.1%

CELC opened at $80.61 on Thursday. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The company’s 50-day moving average is $90.18 and its 200 day moving average is $105.30. Celcuity has a fifty-two week low of $44.42 and a fifty-two week high of $151.02. The firm has a market capitalization of $3.94 billion, a P/E ratio of -18.75 and a beta of 0.19.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Research analysts expect that Celcuity will post -4.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

Hedge funds have recently modified their holdings of the stock. Engineers Gate Manager LP purchased a new position in Celcuity in the second quarter valued at approximately $480,000. IFP Advisors Inc purchased a new stake in Celcuity in the second quarter worth $73,000. Nykredit A S purchased a new stake in Celcuity in the second quarter worth $119,000. Corient Private Wealth LP purchased a new stake in Celcuity in the second quarter worth $1,258,000. Finally, Headlands Technologies LLC bought a new stake in shares of Celcuity in the second quarter valued at $980,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.

The company’s primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient’s tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.

Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs.